Pasithea Therapeutics Income Statement (2021-2026) | KTTA

1Y3Y5Y7Y10YAll
Download Data
Income Statement Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026
Revenue & cost
Revenue (Quarter)
0.01M0.01M0.22M0.24M
Gross Profit (Quarter)
721.00-0.00M0.13M0.24M
Operating items
Research & Development (Quarter)
1.39M1.10M2.03M1.62M3.35M1.75M2.36M1.58M1.51M1.73M2.15M1.36M2.74M2.94M
Selling, General & Administrative (Quarter)
0.73M1.27M1.95M2.41M2.61M2.58M2.66M2.12M1.80M2.16M1.80M2.29M1.59M1.42M1.75M1.95M1.66M1.75M7.51M1.93M
Restructuring Costs (Quarter)
0.33M655.0045.00
Other Operating Expenses (Quarter)
-3.09M
Operating Expenses (Quarter)
0.73M1.27M1.95M2.73M2.61M2.58M4.04M3.21M3.83M3.79M5.15M4.04M3.95M3.00M3.26M3.68M3.81M3.11M10.26M4.88M
Operating Income (Quarter)
-0.73M-1.27M-1.96M-2.40M-2.61M-3.86M-4.04M-3.21M-3.83M-3.79M-5.15M-4.04M-3.95M-3.00M-3.26M-3.68M-3.81M-3.11M-10.26M-4.88M
EBIT (Quarter)
-4.88M
Non-operating items
Interest & Investment Income (Quarter)
0.45M
Non Operating Investment Income (Quarter)
-0.01M
Other Non Operating Income (Quarter)
-0.01M
Non Operating Income (Quarter)
2.01M
Net income details
EBT (Quarter)
-2.87M
Profit After Tax (Quarter)
-2.87M
Income from Continuing Operations (Quarter)
-2.87M
Consolidated Net Income (Quarter)
-2.87M
Income towards Parent Company (Quarter)
-2.87M
Net Income towards Common Stockholders (Quarter)
-2.87M
Additional items
EPS (Basic) (Quarter)
-0.12
EPS (Weighted Average and Diluted) (Quarter)
-0.12
Shares Outstanding (Weighted Average) (Quarter)
24.34M
Shares Outstanding (Diluted Average) (Quarter)
24.34M
EBITDA (Quarter)
-2.84M
Interest Expenses (Quarter)
0.01M-0.12M
Shares Outstanding (Quarter)
24.94M